






Title of Document:  REVIEW OF THE MOLECULAR BIOLOGY AND 
EPIDEMIOLOGY OF INFECTIOUS 
LARYNGOTRACHEITIS (GALLID HERPESVIRUS-1) 
 
Kimberly Rae Menendez, Master of Science, 2012 
 
Directed By:   Associate Professor, Nathaniel L. Tablante 
    Veterinary Medical Sciences 
 
 
A review of the molecular biology and epidemiology of avian infectious laryngotracheitis 
(ILT) is conducted due to the outdated state of current ILT review material.  The 
objective of this review is to include updated information on the molecular biology of 
Gallid herpesvirus 1 (GaHV-1), the causative agent of ILT, and to present the latest 
information on the molecular epidemiology of ILT.  Recent developments in molecular 
biology specific to GaHV-1 have been made and are highlighted in this review, and the 
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Chapter 1: Introduction 
 
Rationale and Objectives 
Infectious laryngotracheitis (ILT) is an upper respiratory tract disease of chickens, 
pheasants, and peafowl caused by the alphaherpesvirus Gallid herpesvirus 1 (GaHV-1) 
(Guy & Garcia, 2008).  The virus is shed in respiratory secretions, easily transmitted 
from bird-to-bird by inhalation of secreted droplets, and commonly carried and 
additionally transmitted by poultry facility workers and fomites.  ILT is characterized by 
acute respiratory disease and mild to severe clinical signs involving the upper respiratory 
tract including conjunctivitis, nasal discharge, coughing, sneezing, and expectoration of 
bloody mucous.  ILT occurs worldwide and severity of clinical signs and mortality rate, 
which can range from 0-70%, depending on virulence of the infective strain (Oldoni et 
al., 2009).  The virus is responsible for frequent outbreaks in high-density poultry 
producing areas, which are often associated with large economic losses (Bagust et al., 
2000). 
Since the initial description of ILT in the early 20th century, the disease has 
remained a problem for the global poultry industry, causing morbidity and mortality 
related loses each year.  Both the layer and broiler industries are affected, although the 
broiler industry is affected to a larger extent.  In the vertically integrated broiler industry, 
large companies contract growers to raise their birds using company specifications, 
during which time a grower incurs any loss during the grow-out process.  As a result, ILT 
related losses specifically affect the individual grower.  Current control measures, 
including chicken embryo origin (CEO) and tissue culture origin (TCO) live-attenuated 
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vaccines, reduce the impact of losses.  However, they often perpetuate release of live 
virus into the field leading to virulence reversion of vaccine virus, which can cause 
outbreaks of vaccinal laryngotracheitis (VLT) (Dufour-Zavala, 2008).  However, based 
on the low cost and time efficiency of live-attenuated vaccination on a per-bird basis, 
contract growers continue to select these vaccines to reduce morbidity and mortality 
related losses. 
Progress in the areas of ILT prevention and control would significantly decrease 
health related production losses in these sectors of animal agriculture, and development 
of improved or novel vaccines will ultimately guide these improvements.  However 
characteristics relating to the molecular biology and epidemiology of GaHV-1 remain 
undefined and limit ILT technological advances.  While much is known about the 
structure of the virus and its genome, the mechanisms responsible for virulence reversion 
are yet to be fully understood.  Recently, investigation into attenuation and virulence 
reversion has begun, and further investigation characterizing genes involved in viral 
pathogenesis is a primary focus of current ILT genetics. 
In addition to the fields of ILT molecular biology and epidemiology, recent 
epigenetic study on host-pathogen interactions of the ILT and chicken genomes has been 
launched.  Aimed at the transcriptional level of the genome and invested in elucidating 
the effects of infection on host gene expression, ILT epigenetics seeks to identify those 
factors involved in viral pathogenesis and host resistance to infection.  Additionally, 
GaHV-1 contains many genetic differences from other related herpesviruses and has host 
tropism with high specificity for chickens, indicating potential for ILT-specific 
mechanisms to be discovered. 
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With novel technologies opening new investigative pathways, much of the review 
literature available for ILT is out of date.  The aim of this literature review is to bring 
together new information, and to touch upon six major issues related to ILT molecular 
biology, epidemiology, and epigenetics. 
1. Review GaHV-1 molecular biology. 
2. Outline the historical implications of live-attenuated vaccine 
development in shaping current molecular epidemiology of GaHV-1. 
3. Outline the current implications of live-attenuated vaccine use in 
shaping the current global and molecular epidemiology of GaHV-1. 
4. Review the global and molecular epidemiology of the GaHV-1. 
5. Review the current epigenetic findings involving host-virus 
interactions. 
6. Outline the significance of molecular biology, epidemiology, and 
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Chapter 2: Molecular Biology of Gallid Herpesvirus-1 
 
2.1 Viral Morphogenesis and Chemical Composition 
 In 1931, experiments first defined the causative agent of ILT as a filterable virus 
(Beach, 1931), and the nucleic acid content was confirmed to be DNA and similar to that 
of the herpesvirus group (Tannock, 1965).  The molecular weight of the virus was 
estimated by restriction endonuclease fragment summation and approximated to be 
between 102.1 x 106 to 97.35 x 106 Daltons (Kotiw et al., 1982).  Electron microscopy 
confirmed the typical herpesviral morphology of GaHV-1 (Figure 1), and the virus 
consists of an icosahedral DNA containing capsid at its core and is surrounded by a 
tegument layer and an outer envelope with embedded surface glycoproteins (Fuchs et al., 
2007).   
 
2.2 Viral Genome 
The genome of GaHV-1 is composed of a linear, double-stranded DNA molecule.  
Among the seventeen complete genome sequences currently available on GenBank, the 
size of the GaHV-1 genome ranges from 148-kb to 155-kb, with size variations attributed 
to single nucleotide polymorphisms (SNPs) as well as insertions and deletions (INDELs) 
between strains (Lee et al., 2011a.b; Chakma et al., 2012; Lee et al., 2012; Spatz et al., 
2012).  The genome is comparable to that of other alphaherpesviruses and contains the 
prototypic unique long (UL) and unique short (US) regions.  However, it does not contain 
characteristic repeat regions flanking the UL region of the genome (Waidner et al., 2011), 
and instead inverted repeats flank only the US region (Guy & Garcia, 2008) (Figure 2).  
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Figure	  1:	  Electron	  microscopy	  from	  Fuchs	  et	  al.	  (2007)	  of	  GaHV-­‐1	  virion	  exiting	  the	  
host	  cell	  via	  exocytosis	  from	  chicken	  Leghorn	  male	  hepatoma	  (LMH)	  cells	  18	  hours	  





































































































































































































































































































































	   7	  
Seventy-seven open reading frames (ORFs) encode for either predicted or 
demonstrated proteins (Guy & Garcia, 2008), sixty-three of which share homology with 
genes of herpes simplex virus 1 (HSV-1) (Fuchs et al., 2007).  The UL3.5 ORF of the 
GaHV-1 genome is not present within the HSV-1 genome, but is common to other 
alphaherpesviruses such as porcine pseudorabies virus (PrV) and varicella zoster virus 
(VZV) (Fuchs et al., 2007).  GaHV-1 contains many other unique genomic 
characteristics, indicating its phylogenetic divergence from other alphaherpesviruses, 
starting with the absence of a typically highly conserved UL16 gene homolog (Fuchs & 
Mettenleiter, 1999).  The viral genome also contains a large internal inversion similar to 
one found within the genome of PrV but absent in alphaherpesviruses such as HSV-1, 
VZV, and equine herpesvirus 1 (EHV-1), and this internal inversion is comprised of a 
gene cluster spanning from the UL22 to the UL44 ORFs of the UL region (Ziemann et al., 
1998a).  A UL47 homolog, typical of the UL region of many alphaherpesviruses, is absent 
in the equivalent region of the GaHV-1 genome and is instead translocated between the 
US3 and US4 ORFs of the US region (Helferich et al., 2007c).  Five ORFs in the UL 
region, ORF A to ORF E, are unique to both GaHV-1 and psittacid herpesvirus (PsHV-
1), an alphaherpesvirus of psittacine birds (Thureen & Keeler, 2006).  In addition to these 
5 ORFs, GaHV-1 and PsHV-1 share similarities in the region between the UL22 and 
UL44 ORFs, as well as the translocation of the UL47 ORF, defining these viruses as the 
only two members of the family Iltoviridae (Thureen & Keeler, 2006).  Lastly, a 
paralogous pair of genes, UL0 and UL[-1], represent a unique duplication in the GaHV-1 
genome and are evidence of an evolutionary duplication of a spliced GaHV-1 distinct 
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gene (Ziemann et al., 1998b).  These characteristics of the GaHV-1 genome are also 
illustrated in Figure 2. 
 
2.3 Viral Replication 
 While GaHV-1 entry has yet to be fully explained, structural glycoprotein C (gC) 
has been confirmed as an accessory entry protein (Pavlova et al., 2010).  Based on HSV-
1, other proteins involved in attachment and entry include structural glycoproteins gB, 
gD, gH, and gL, the process beginning with gB or gC interaction with heparin sulfate 
proteoglycans, followed by interaction of gB, gD, and a gH-gL complex to trigger merger 
of viral and cellular membranes and release of the tegument and nucleocapsid into the 
host cell cytoplasm (Akhtar & Shukla, 2009; Thureen & Keeler, 2006).  However, an 
apparent disparity in the entry process exists, as GaHV-1 entry is most likely heparin-
independent, pointing to a pathway alternative to that of HSV-1 (Pavlova et al., 2010). 
 Following release into the cytoplasm, the nucelocapsid is transported to the 
nuclear membrane where viral DNA is released, allowing for migration of viral DNA into 
the nucleus via nuclear pores where transcription and replication of viral DNA occur 
(Guy & Garcia, 2008).  Gene expression has been displayed to occur in a cascade pattern 
similar to other alphaherpesviruses (Figure 3) (Prideaux et al., 1992), and much 
information about GaHV-1 DNA replication has also been adapted from HSV-1.  
Immediately-early (IE or alpha) genes are the first to be expressed in the nucleus of 
infected cells, the protein products of which stimulate expression of early (E or beta) 
genes required for DNA replication, subsequently stimulating expression of late (L or 
gamma) genes encoding for viral structural proteins (Knipe & Cliffe, 2008).   
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GaHV-1 nuclear egress begins with translocation of the capsid through the 
nuclear membrane after pro-capsid packaging of monomeric DNA, followed by addition 
of an envelop from the inner membrane of the host cell nucleus and movement to the 
lumen of the endoplasmic reticulum into vacuoles within the cytoplasm (Guo et al., 
1993).  Mature capsid-less particles are formed in the trans-Golgi region of the 
cytoplasm, where assembly of tegument and secondary envelopment occur, and 
infectious virions are subsequently released by exocytosis (Fuchs et al., 2007).  In vitro 
replication kinetics have shown DNA replication beginning between 8 and 12 hours post 
infection (hpi), with exponential increases in virus titer between 11 and 24 hpi, indicating 
the peak of viral replication within this period (Prideaux et al., 1992). 
 
2.4 Viral Proteins 
 The cascade pattern of GaHV-1 protein expression begins with a short period of 
alpha (α) polypeptide expression, followed by beta (β) polypeptide expression between 4 
to 16 hpi, and gamma (γ) polypeptide expression divided into γ1 and γ2 expression 
maintained from 4 and 8 hpi respectively (Prideaux et al., 1992).  α products are non-
structural polypeptides responsible for regulation of β and γ gene products, and are 
additionally self-dependent on their own production for downregulation of transcription.  
β products include enzymes critical for DNA synthesis such as DNA polymerase and 
thymidine kinase (TK), and γ products include structural proteins such as surface 
glycoproteins (Post et al., 1981; Prideaux et al., 1992).  
 
2.4.1 Alpha and Beta Proteins 
Non-structural proteins, majority of which are expressed as α and β proteins, are 
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critical to regulatory functions of viral infection.  While description of these proteins 
specific to GaHV-1 is far from complete, functional characterizations exist, some of 
which have been adapted from other herpesviruses. 
α genes are able to express in the absence of protein synthesis and consist of 
regulatory genes such as the infected cell protein (ICP) family.  The GaHV-1 gene coding 
for ICP4 is the only ICP described in detail for GaHV-1 and shares sequence and 
functional homology to that of HSV-1 (Johnson et al., 1995c).  Of the five regions of the 
GaHV-1 ICP4 protein, two exist with considerable homology to other 
alphaherpesviruses, with region 4 the most conserved and critical to γ gene expression. 
Least conserved, region 5 exists as a comparatively larger protein region in GaHV-1 and 
contains a second serine run, indicating additional sites for phosphorylation and increased 
overall activation potential when compared to other herpesviruses.  Further functional 
investigation of GaHV-1 ICP4 has yet to be done, however ICP4 resides in the nucleus of 
HSV-1 infected cells, mediates the switch from α to β and γ expression, mediates down-
regulation of its own expression following the onset of viral protein expression, and 
requires minimal promoters containing simple TATA homologies for transactivation 
(Dixon & Schaffer, 1980; Knipe et al., 1987; Smith et al., 1993; Helferich et al., 2007a).  
In addition to ICP4 description, a region homologous to HSV-1 ICP27 has been 
described for GaHV-1, while sequence homologies of the UL3 and UL4 products suggest 
colocalization of these proteins with ICP22 in GaHV-1 nuclear inclusion bodies as seen 
with other herpesviruses (Johnson et al., 1995b; Fuchs & Mettenleiter, 1996; Xing et al., 
2011). 
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Additional amino acid sequence comparisons have revealed GaHV-1 proteins 
with homology to those of other herpesviruses and with specific roles in DNA 
replication.  The UL2 product encodes two conserved amino acid stretches considered 
signature uracil-DNA glycosylase (UDG) sequences among alpha-, beta-, and 
gammaherpesviruses, and indicates that GaHV-1 UL2 retains equivalent UDG functional 
activity (Fuchs & Mettenleiter, 1996).  Also, the GaHV-1 UL5 product contains six 
functionally conserved helicase motifs, predicting conserved function in DNA replication 
in the form of a helicase-primase subunit complexed with the UL8 and UL52 proteins as 
seen in other alphaherpesviruses (Fuchs & Mettenleiter, 1996; Chen et al., 2011).  The 
GaHV-1 UL50 product shows conservation of typical deoxyuridine triphosphatase 
(dUTPase) function, essential to nucleotide metabolism during DNA replication, despite 
loss of the first five domains seen among mammalian alphaherpesviruses (Fuchs et al., 
2000). 
 Dependent on α gene expression, β gene expression results in enzymes critical for 
DNA synthesis.  One such enzyme described for GaHV-1 is the TK gene product.  With 
27.9% amino acid sequence identity to HSV-1 TK, portions of the protein corresponding 
to the nucleotide binding domain are well conserved, while non-conserved regions 
suggest GaHV-1 TK to have unique substrate-binding specificities when compared to 
mammalian herpesviruses (Keeler, 1991). 
 
2.4.2 Gamma Proteins 
γ gene expression is responsible for structural protein products including 
tegument and glycoproteins.  Traditionally, herpesviral structural glycoproteins have 
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been described as mediators of virus entry, cell fusion, and viral egress, as well as 
important immunogens and targets of cell-mediated immunity (Poulsen & Keeler, 1997).  
GaHV-1 glycoproteins share homology to those of other alphaherpesviruses, however 
direct characterization of these proteins specific to GaHV-1 remains incomplete.  DNA 
sequencing has confirmed that GaHV-1 encodes structural proteins homologous to HSV-
1 including gK, gN, gH, gB, gC, gM, gL, gG, gJ, gD, gI, and gE, from the UL53, 
UL49.5, UL22, UL27, UL44, UL10, UL1, US4, US5, US6, US7, and US8 genes 
respectively (Devlin et al., 2006a).  The first full composite genome sequence of GaHV-1 
was compiled from fourteen published partial sequences (GenBank accession number 
NC_006623.1), with identification of genes and their functions based on that of other 
herpesviruses and indicative of GaHV-1 glycoproteins in functions such as virion 
morphogenesis, membrane fusion, cell entry, cell-to-cell spread, cell attachment, binding 
of complement factors, and binding of cell surface receptors (Thureen & Keeler, 2006). 
Limited investigation into specific GaHV-1 structural proteins has revealed that 
gK is encoded from a late transcript that shares significant homology to that of HSV-1 
and contains characteristics of a membrane-bound glycoprotein (Johnson et al., 1995b).  
Conserved herpesviral gene products gM and gN have been shown to form a complex, 
with correct processing of O-glycosylated gN depending on complex formation with non-
glycosylated gM (Fuchs & Mettenleiter, 2005).  gB is initially synthesized as a 110 kDa 
monomeric precursor protein, which is first processed into 100 kDa subunits, and further 
proteolytically cleaved into two disulphide-linked species of 58 kDa each (Griffin, 1991; 
Poulsen & Keeler, 1997).  gC and gJ have been shown to localize in the outer viral 
envelope (Veits et al., 2003a).  Additionally, gC contains low amino acid sequence 
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homology to other herpesviruses, as well as an extracellular charged region typical of 
herpesviral interaction with cell surface proteoglycans, and is a glycosylated protein 
product of late gene expression (Kingsley et al., 1994).   
The gG protein is secreted from GaHV-1 infected cells and plays a role in 
inflammatory response at the site of infection as a likely viral chemokine binding protein 
(vCKBP) (Devlin et al., 2006b; Helferich et al., 2007a).  gI and gE of other herpesviruses 
have been displayed to form a heterodimer with Fc receptor binding activity, and are 
pivotal to cell-to-cell spread of GaHV-1 (Davis-Poynter & Farrell, 1996; Devlin et al., 
2006a).  The role of gD as a GaHV-1 glycoprotein is based upon regions of significant 
homology to other herpesviruses, specifically the positioning of six cysteine residues that 
are conserved among all gD amino acid sequences (Johnson et al., 1995a). gL functional 
homologues co-processed and complexed with gH can be found in many herpesviruses 
including GaHV-1, and presence of a N-terminal signal sequence, N-glycosylation site, 
and two cysteine residues suggest similar function for the GaHV-1 protein  (Fuchs & 
Mettenleiter, 1996). 
Herpesviral tegument proteins, which form the protein layer between the 
nucleocapsid and viral envelope, are primarily structural in function but additionally 
regulate functions such as capsid transport during viral entry and egress, targeting of the 
capsid to the nucleus, regulation of transcription, translation and apoptosis, DNA 
replication, immune modulation, cytoskeletal assembly, and viral assembly and egress 
(Kelly et al., 2009).  While each of these roles has not been individually described for 
GaHV-1, a few have been identified.  The membrane associated UL11 tegument protein, 
located in both mature virons and cytoplasm of infected chicken cells, has been shown to 
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be essential for secondary envelopment of GaHV-1 (Fuchs et al., 2012).  UL37 as well as 
UL46, UL47, UL48, and UL49 are also identified GaHV-1 tegument proteins, each with 
unique characteristics (Helferich et al., 2007a).  UL37, UL46, and UL49 accumulate in 
the cytoplasm of syncytia but are absent from infected nuclei, confirming cytoplasmic 
location of tegument addition relevant to secondary envelopment of the virion.  However, 
UL47 and UL48 accumulate in the cytoplasm and in larger portions within the nuclei of 
GaHV-1 infected cells, consistent with a role in viral gene expression as well as 
secondary envelopment.  Additionally, UL48 is important in the onset of viral gene 
expression and enhances α gene promoters such as those for ICP4. 
In addition to tegument and glycoproteins, other GaHV-1 γ genes capable of 
nuclear accumulation include UL0, UL[-1], and UL31.  As previously described, UL0 
and UL[-1] result from a duplication unique to the GaHV-1 genome, and their nuclear 
targeting is hypothesized to be a product of polypeptide sequences rich in arginine, with 
functions possibly involved in host gene expression, encapsidation of viral DNA, or as 
structural components of nucleocapsid assembled within the host cell nucleus (Ziemann 
et al., 1998b).  Nuclear accumulation of UL31 has been alternatively correlated with 
possible function in nuclear egress due to peripheral localization along the nuclear 
membrane of host cells (Helferich et al., 2007a). 
 While structure-function analysis remains incomplete, protein function in relation 
to in vivo viral virulence has been investigated for a few of the GaHV-1 proteins.  In the 
absence of gG, clinical sings, mortality, and effects on weight gain are reduced, while an 
increase in tracheal thickness is representative of an increase in inflammatory cell 
infiltration and supportive of the role of gG as a vCKBP (Devlin et al., 2006b).  A 
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decrease in clinical symptoms, in addition to a decrease in microscopic tracheal lesions, 
is also seen in the absence of TK (Han et al., 2002), while little to no clinical signs and 
viral shedding occurring in the absence of UL0 (Veits et al., 2003b).  Similar effects 
occur with UL47, with a decrease in clinical signs, viral shedding, and tracheal lesions in 
the absence of the gene (Helferich et al., 2007b).  Additionally, good protection 
efficiency for TK, UL0, and UL47 against virulent virus challenge suggests vaccine 
candidacy for mutants of these genes, while in ovo vaccine delivery of gG deficient virus 
to embryos at 18 days of incubation is able to protect birds from challenge 20 days post 
hatch (Legione et al., 2012).  While these vaccines suggest safe and efficacious new 
vaccine candidates, the issue of vaccine virus tracheal replication and shedding is still 
apparent, as exemplified by gG deficient virus retention of tracheal replication, and the 
capacity of these viruses to revert to virulence when passed from bird-to-bird has yet to 
be sufficiently investigated. 
 
2.5 Host Immunity and Viral Immune Evasion 
 Following GaHV-1 infection, the humoral immune response produces detectable 
levels of antibody.  Following infection, virus-neutralizing antibodies are detectable 
within 5 to 7 days and peak at 21 days, after which they begin to decline but remain 
detectable for up to 1 year (Guy & Garcia, 2008), possibly generated by long lasting 
plasma cells.  Secreted antibodies within the trachea are detectable beginning at 7 days, 
and IgA- and IgG-plasma cells begin to increase between days 3 and 7 after infection.  
Although a role of humoral immunity in GaHV-1 infection is apparent, the importance of 
cell mediated immunity over humoral is exemplified by the ability of bursectomized 
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birds, unable to produce specific antibodies, to resolve primary infections as efficient as 
birds retaining functional bursae of Fabricius (Fahey & York, 1990).  Additionally, poor 
correlation is typically seen between antibody titers and immune status of flocks (Guy & 
Garcia, 2008).  However, little research directly investigating the cell-mediated immune 
response to GaHV-1 has been done.  In terms of passive immunity, maternal antibodies 
are transferred to offspring, however protection is not conferred and transferred 
antibodies do not interfere with vaccination (Hayles et al., 1976). 
Evaluation of enzyme-linked immunosorbent assay (ELISA) titers in birds has 
been a useful method of diagnosis in the past, and titers are typically detectable within 2 
weeks of exposure and for 4 to 7 weeks following (Sander & Thayer, 1997).  However, 
currently more precise methods of diagnosis such as histopathology and quantitative PCR 
(qPCR) using GaHV-1 gene specific primers are utilized for definitive diagnosis. 
The virus itself codes for immune evasion mechanisms characteristic of 
herpesviruses, and alpha-, beta-, and gammaherpesviruses each encode for proteins with 
functions including inhibition of complement, antibody function, cellular immunity, and 
the cytokine network, as wells as coding for functional homologues of cytokines, 
chemokines, and their receptors (Davis-Poynter & Farrell, 1996).  Specific to 
alphaherpesviruses are the functions of gC, gE, gG, and gI.  A complex protein consisting 
of gE and gI has been functionally described as having Fc receptor binding activity of 
immunoglobulins such as IgG, and gC has been associated in the blocking of complement 
activation through binding of component C3, and derivatives such as C3b, for 
alphaherpesviruses such as HSV-1 (Davis-Poynter & Farrell, 1996).  The functions of 
gC, gE, and gI have not been specifically described for GaHV-1, although their sequence 
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homologies suggest that they do in fact retain functional homology, however host 
immune mediation by GaHV-1 gG has been displayed and function of the protein as a 
vCKBP is currently accepted (Devlin et al., 2006b). 
 
2.6 Viral Pathobiology 
 GaHV-1 typically gains entry via the mucous membranes of the upper respiratory 
tract or ocular tissue of the host.  Following GaHV-1 infection, an average incubation 
period of 4 days occurs, with onset of clinical signs occurring between 2 and 12 days 
post-infection (dpi), a shorter time period typical of experimental infection, and with 
severity of clinical signs dependent on host age as well as infective dose and strain 
(Hughes et al., 1987; Guy & Garcia, 2008; Tablante & Menendez, 2010).  Peak viral 
shedding occurs between 2 and 4 dpi, directly correlated to the viral replication cycle.  
Induction of mild to severe histopathological lesions within the tracheal epithelium 
occurs concurrently to clinical sign development, and level of severity is also associated 
with infective strain.  Figure 4 illustrates a histopathological section of a chorioallantoic 
membrane from a virulent GaHV-1 United States Department of Agriculture (USDA) 
reference strain infected embryo showing mild diffuse heterophilic cellulitis and typical 
herpesviral syncytia including intranuclear eosinophilic inclusion bodies.    
ILT clinical signs include conjunctivitis, nasal discharge, and decreased 
production efficiency, and in more severe forms, gasping, coughing, and expectoration of 
bloody mucus may develop (Figure 5).  While genes specifically responsible for 
development of clinical signs have not been fully elucidated, the loss of or decrease in 
clinical signs in the absence of gG, TK, UL0, and UL47 directly correlates these genes to  
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Figure 4: (20x magnification) Chorioallantoic membrane (CAM) from a chicken embryo 
infected at 10 days of development with USDA reference strain GaHV-1.  At 5 dpi, CAM 
tissue was harvested and fixed in buffered formalin.  Specimens were further processed, 
embedded in paraffin, sectioned to 4-µm thickness, and stained with Hematoxylin & 
Eosin (H&E).   Tissues were microscopically evaluated by an ACVP-certified veterinary 
anatomic pathologist in a blinded fashion for evidence of herpesviral infection.  Sloughed 
epithelial cells exhibited prominent eosinophilic intranuclear inclusions (small arrow) and 
formation of syncytia (large arrow) typical of herpesviral infection.   Inset: Herpesviral 












Figure 5: In a study to investigate incubation period, shedding, and immune response of 
commercial broiler chickens to GaHV-1 infection, 15 specific pathogen free birds were 
divided into 5 groups and inoculated with differential doses of the virulent United States 
Department of Agriculture (USDA) reference strain of GaHV-1 at 14 days of age.  Group 
1 were inoculated with a dose level of 1.7x103 TCID50/ml, group 2 a dose level of 
3.4x103 TCID50/ml, group 3 a dose level of 5.1x103 TCID50/ml, group 4 a dose level of 
6.8x103 TCID50/ml, and group 5 sterile phosphate buffered saline at a volume of 0.1 ml to 
serve as the control group.  All infected birds displayed varying clinical sings beginning 
at 4 days post infection, including coughing, sneezing, caseous plug (arrow) formation 
due to increased exudate within the tracheal lumen (A), inflamed conjunctival tissue (B), 
and/or ILT characteristic extension of the neck associated with caseous plug formation 
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host response to infection.  Morbidity and mortality of ILT related to clinical signs and 
severe respiratory disease range from 5% to 70%, however a range of 10% to 20% is 
more typical of outbreaks due to mild strains of the virus (Guy & Garcia, 2008).   
Morbidity and mortality related losses negatively affect the global poultry 
industry each year and are still present despite vaccine related control efforts.  
Additionally, development of a carrier state in birds and establishment of latency, 
following infection or vaccination, coupled with viral reactivation further complicate the 
issue (Hughes et al., 1987; Tablante & Menendez, 2010).  Development of vaccine 
alternatives has yet to provide a suitable alternative to the industry, with further 
developments reliant on molecular advances, leaving biosecurity as the most critical 
factor to preventing current outbreaks that are typically capable of spreading rapidly.   
The mechanism of spread has not been fully explained, however wind-borne 
spread of the virus has been associated with transmission, as well as vehicle related farm-
to-farm traffic, farm employee hygiene and personal protective equipment use, and farm 
equipment such as tunnel ventilators and shared litter removal equipment (Johnson et al., 
2005; Volkova et al., 2012).  Strict adherence to simple hygiene measures and biosecurity 
are capable of abrogating spread of the virus, and inactivation of the virus outside of the 
host is easily attained using low levels of heat or disinfectants (Bagust et al., 2000).  For  
the California broiler industry, a strategy involving extended downtime of flocks, in 
addition to implementation of an extensive biosecurity audit in response to ILT outbreaks 
beginning in 2005, has substantially decreased the occurrence of ILT in the entire state to 
a rate of 1.25% between May 2010 and April 2012 (Chin et al., 2009; Shivaprasad, 
2012). 
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Chapter 3: Historical and Current Vaccine Strategies Related to ILT  
Molecular Epidemiology 
 
3.1 Discovery of ILT and Early Vaccine Development 
To introduce the molecular epidemiology of ILT, an understanding of the origin 
and usage of ILT vaccines is necessary.  The disease ILT was first confirmed in 1925 in 
Canada, followed by the United States in 1926, Australia & Great Britain in 1935, and 
Europe in 1940 (Cover, 1996).  By 1962, ILT was described in at least 40 countries in the 
FAO-WHO-OIE Animal Health Yearbook (Pulsford, 1963).  In 1934 C.S. Gibbs 
described the first vaccination method for ILT (Gibbs, 1933, 1934).  Brush vent 
application with live virulent virus from tracheal scraping preparations was recommended 
and shown to provide year-long protection to birds showing takes, or inflammation of the 
cloacal mucosa typically seen 3 to 8 days after brush vent application.  However, vent 
vaccination was also described to release live virulent virus into the field, allowing for 
continued spread of the virus. 
 
3.2 Live-attenuated Vaccine History 
Development of the chorioallantoic (CAM) virus propagation method in 1935 by 
C.A. Brandly gave way to efforts in the 1950s and 1960s to attenuate field strains for the 
development of strains of weaker virulence for vaccine use, higher environmental safety, 
and improved efficacy (Brandly, 1935).  Worldwide adoption of this method, coupled 
with successive in ovo passage of field viruses, gave rise to various strains of attenuated 
virus.  The Cover, Hudson, Samberg, SA-2, A20, and Serva vaccine strains (Table 1), all  
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Table	  1:	  Examples	  of	  live-­‐attenuated	  ILT	  vaccines	  from	  across	  the	  globe.	  	  Many	  of	  
the	  strains	  utilized	  to	  make	  the	  TCO	  vaccine	  (LT-­‐IVAX)	  and	  the	  many	  CEO	  vaccines	  
available	  today	  originated	  in	  the	  1950s	  and	  1960s.	  	  Since	  that	  time,	  the	  ability	  of	  
these	  vaccines	  to	  spread	  from	  bird-­‐to-­‐bird	  and	  cause	  vaccine-­‐related	  outbreaks	  of	  
ILT	  has	  been	  described	  and	  remains	  a	  large	  problem	  for	  the	  poultry	  industry.	  *While	  
the	  current	  LT-­‐IVAX	  product	  label	  does	  not	  cite	  the	  strain	  name,	  the	  original	  strain	  





Vaccine	  Name,	  Company	   Country	  of	  Origin	   Strain	  
Poulvac	  Laryngo	  A20,	  Fort	  Dodge	   Australia	   A20	  
Avipro	  ILT	  vac,	  LAHi	   USA	   Hudson	  
Avivac	  ILT,	  Avivac	   Russia	   VNIIBP	  
BIO	  Laringo	  PV,	  Merial	   Italy	   PV	  09	  
Himmvac,	  KBNP	   South	  Korea	   IVR-­‐12	  
ILT,	  Abic	   Israel	   Samberg	  
ILT	  Vac,	  Merial	   France	   T20	  
Infectious	  Laryngotracheitis	  Vaccine	  
Living,	  Qilu	  Animal	  Health	  
China	   K317	  
Izovac	  ILT,	  IZO	   Italy	   PV/64	  
Laringovac,	  Pasteur	  Institute	   Romania	   LT-­‐79-­‐2	  
Larivac,	  Romvac	   Romania	   ILT	  90	  
Laryngo-­‐Vac,	  Pfizer	   USA	   Cover	  	  
Living	  Vaccine	  of	  Fowl	  
Laryngotracheitis,	  Qingdao	  Yebio	  	  
China	   K317	  
LT-­‐Blen,	  Merial	   USA	   Hudson	  
LT-­‐IVAX,	  Merck	   USA	   ASL L-6*	  
Medivac	  ILT,	  Medion	   Indonesia	   A	  94	  
Nobilis	  ILT	  Vaccine,	  Intervet	   Netherlands	   Serva	  
Poulvac,	  Pfizer	   UK	   Salisbury	  146	  
Poulvac	  Laryngo	  A20,	  Pfizer	   Australia	   A20	  
Poulvac	  Laryngo	  SA2,	  Pfizer	   Australia	   SA2	  
Rinbio	  ILT,	  Ringpu	   China	   K317	  
Poulvac	  Laryngo	  SA2,	  Fort	  Dodge	   	   Australia	   SA-­‐2	  
Trachivax,	  Merck	   USA	   Hudson	  
Vaksi	  ILT,	  Vaksindo	  Satwa	  
Nusantara	  
Indonesia	   Hudson	  
Vir	  101,	  Biovac	   Israel	   Samberg	  
Volvac	  LT	  MLV,	  Boehringer	  
Ingelheim	  
Mexico	   N-­‐71851	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still in current use, were derived using variations of the CAM attenuation method, and are 
currently referred to as chick embryo origin (CEO) vaccines.   
Cover and Benton first described United States field strains in 1958 with lower 
levels of virulence when administered to birds, capable of protecting birds against 
challenge 19 days post intratracheal inoculation (Benton et al., 1958), later giving rise to 
the Cover strain CEO vaccine.  In a United States patent submitted by C.B. Hudson in 
1969, the Hudson strain CEO vaccine was created after 191 in ovo passages, producing 
an attenuated virus intended for ocular, intranasal, or intratracheal vaccination.  Methods 
included inoculation of the CAM of 9 to 12 day old embryonated chicken eggs, followed 
by collection of infected CAMs 5 days post inoculation, and preparation of masticated 
membranes for vaccination (Hudson, 1969).   
In Israel, virus from acute field cases of ILT were utilized to create a vaccine from 
18th passage CAM material, produced in a similar fashion as the Hudson methods using 
chicken, duck, and turkey eggs.  The resulting Samberg strain CEO vaccine was intended 
for intra-ocular or vent-brush application (Samberg & Aronovici, 1969a).  In Australia, 
the SA2 vaccine strain was also developed as a chicken embryo attenuated strain in 1966 
from Australian field isolates, and was later further attenuated in chicken embryonic cell 
culture to generate the A20 vaccine in 1983 (Kirkpatrick et al., 2006a).  The Serva 
vaccine, also of chick embryo origin, was developed using European based GaHV-1 
strains.  Each of these vaccines not only addressed outbreaks according to regional 
strains, but were time saving in their application routes and, for the first time, presented 
vaccine options that decreased production losses associated with clinical sign 
manifestation following live virus vaccination. 
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3.3 Effect of Live-attenuated Vaccines on Viral Epidemiology 
While positive factors associated with the newly labeled CEO vaccines 
accomplished many of the goals of the time, Samberg described two negative factors still 
controversial with CEO use today.  In addition to noting a failure in the drinking water 
vaccination method (Samberg & Aronovici, 1971), the tendency of the attenuated virus to 
spread to unvaccinated in-contact birds was also described.  This phenomenon, also 
described by others developing CEO vaccines at that time, was attributed to an increase 
in virulence beginning with the 7th back passage of the Samberg strain in unvaccinated 
birds (Samberg & Aronovici, 1969b).   
Despite these indications, a large portion of the poultry industry adopted both 
CEO vaccination and the drinking water application method, which when combined, 
perpetuated the spread of virulent virus.  This spread was, and still is, largely attributed to 
back passage through birds inadequately vaccinated, perpetuating release of live virus 
into the field and the creation of carriers just as live virus vaccination had been negatively 
attributed to beginning in the 1930s.  
The first tissue culture-modified vaccine originated in 1964 (Gelenczei & Marty, 
1964), representing a hopeful new vaccine option, however it too was associated with 
similar drawbacks as the CEO vaccines.  Attenuation of the virulent ASL L-6 virus strain 
was successful in providing birds immunity after 50 serial passages in primary avian cell 
monolayers.  Birds were protected against direct challenge for up to 22 weeks after ocular 
or intranasal application, and the TCO vaccine did so with a decrease in clinical signs.  
However, as with the CEO vaccine, the ability of this virus to spread to unvaccinated 
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birds was described, and the goal of eliminating vaccine associated spread and 
subsequent outbreaks remained unfulfilled. 
 
3.4 Current Chicken Embryo Origin Vaccines 
In today’s industry, live-attenuated vaccine technology has remained vastly the 
same.  Despite the negative implications, birds are still vaccinated with either the TCO 
vaccine or one of the many CEO vaccines currently available in the United States and 
across the globe (Table 1).  This is either performed in a preventive manner, typical of the 
layer industry or with breeding stock, or in the face of an outbreak, as in the case of the 
broiler industry.  Due to the lack of preventive measures in the broiler sector, a large 
majority of outbreaks occur in broiler operations and are directly correlated to their CEO-
centered vaccine strategies.  In the face of an outbreak, CEO vaccine is commonly 
delivered via drinking water to broilers, a method of mass application that relies on 
contact of the vaccine with the nasal cavity during the act of drinking (Robertson & 
Egerton, 1981; Loudovaris et al., 1991a; Devlin et al., 2008). However this method does 
not provide uniform flock vaccination and often results in uneven protection of birds 
allowing for the spread of vaccine virus from vaccinated to non-vaccinated birds.  As a 
result, vaccine responses are prolonged, leading to outbreaks of VLT and potential spread 
to surrounding broiler operations.  
 
3.5 Vaccinal Laryngotracheitis 
Clinical signs associated with VLT outbreaks can range from mild to severe, 
however most broiler operations are willing to bear the comparatively low production 
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losses associated with vaccination as opposed to risking potential losses that would occur 
if the disease were left untreated (Zavala, 2011).  These practices, coupled with a short 
two-week acute infection phase, followed by a classic herpesviral latent infection, result 
in a cyclical pattern of outbreaks triggered by stress-induced reactivation of the virus.  
Subsequently, the potential for spread to surrounding operations is common, allowing the 
virus to increase in virulence with each successive passage, and resulting in damaging 
strains of the virus. 
 
3.6 Tissue Culture Origin Vaccines 
The TCO vaccine produces a robust immune response equivalent to that of the 
CEO vaccine, but is milder in its reverted virulent form and is subsequently isolated from 
the field to a significantly lower extent (Rodríguez-Avila et al., 2007).  However, because 
mass application of the TCO vaccine is not an option, with direct delivery methods 
necessary (Gelenczei & Marty, 1964), use in large operations is typically unfavorable for 
producers.  Additionally, the TCO vaccine retains the ability to replicate in the trachea, 
conjunctiva, cecal tonsils, trigeminal ganglia, and cloaca to an equal extent as the CEO 
vaccine.  Localized replication is sustained in the conjunctiva and trachea after eye-drop 
vaccination, and thus the ability to transmit from bird-to-bird, albeit to a lower extent 
than the CEO vaccine, perpetuates VLT outbreaks even with use of the TCO vaccine 
(Rodríguez-Avila et al., 2007). 
 
3.7 Viral Vector ILT Vaccines 
Viral vector vaccines, such as herpesvirus of turkey (HVT) and fowlpox (FP) 
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vectored vaccines, present an alternative option to live-attenuated vaccines altogether.  
They are increasingly safe due to their inability to revert to virulence, can be 
administered in ovo, and lack an impact on production performance.  However, they are 
comparatively high in cost and mass application in adult birds is not possible, rendering 
these vaccines inadequate for broiler industry associated outbreaks.  Recent studies have 
found that these vaccines provide partial protection and reduce clinical signs, but do not 
decrease challenge viral load in the trachea most likely due to an inherent inability to 
induce a sufficient local immune response within the trachea (Johnson et al., 2010).  As a 
result, many poultry industry veterinarians are reluctant to use vaccines that do not elicit 
a robust immune response, leaving birds susceptible to infection, even if these vaccines 
do not revert to virulence and cause VLT outbreaks that are typical of CEO vaccines.  
However, further improvement of viral vector vaccines is warranted, and the desirable 
inability of these vaccines to revert to virulence deserves further development.   
 
3.8 Recombinant ILT Vaccines 
Recently, GaHV-1 recombinant viruses involving deletion or alterations of genes 
such as gG, TK, UL0, or UL47 have been investigated and implicated as suitable targets 
for recombinant vaccine development due to their phenotypic properties (Han et al., 
2002; Veits et al., 2003b; Devlin et al., 2006b; Devlin et al, 2007; Helferich et al., 2007b; 
Legione, et al., 2012).  Of these genes, deletion of gG has been most thoroughly 
described and demonstrated to be a favorable target for vaccine candidacy (Devlin et al., 
2007).  gG deficient mutant virus strains of GaHV-1 have been developed, described in 
vivo, and vaccination via eye-drop and drinking water have been validated (Devlin et al., 
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2007; Devlin et al., 2008; Devlin et al., 2011).   Additionally, while the gG deficient 
candidate strain after eye-drop application can still pass from bird-to-bird, it is able to 
prevent spread of infection with challenge virus, remains attenuated after one passage to 
unvaccinated birds, and is comparable in efficacy to the A20, SA2, and Serva live-
attenuated vaccines (Coppo et al., 2011; Devlin et al., 2011).  However, further 
investigation using larger bird numbers, increased in vivo passage numbers, and in 
different production settings is critical to the progression of this and other recombinant 
vaccine strains. 
 
3.9 CEO and Recombinant ILT Vaccination 
In recent years, a combination of recombinant and CEO vaccination has been 
investigated in the United States broiler industry.  While intuitively greater in expense, 
CEO vaccination of birds within the zone and live haul routes of outbreak areas, in 
addition to simultaneous in ovo recombinant vaccination at hatchery facilities, sets up for 
the first time a combination treatment and preventive strategy against ILT (Burleson, 
2012). 
 
3.10 Future ILT Vaccines 
Potential for future vaccine development and utilization performed in a manner 
more strategically executed compared to past vaccines is apparent, and synchronization 
of poultry health and production in a way that controls outbreaks of GaHV-1 is in the 
horizon (Devlin et al., 2011).  However, ease of use, cost, effectivity, and availability 
ultimately motivate the majority of producers and poultry health personnel across the 
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globe to use live-attenuated vaccines, thus perpetuating VLT outbreaks and continually 
shaping the epidemiology of the virus.  Furthermore, continued host-to-host passage and 
spread of the virus due to past and current vaccine strategies continues to mold the 
epigenome of the virus.  Understanding these changes, based on virulence reversion, 
holds potential for better discernment of the genes responsible for continued spread of the 
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Chapter	  4:	  Global	  and	  Molecular	  Epidemiology	  of	  ILT 
 
4.1 Global Epidemiology 
Based on outbreak data from the World Organization for Animal Health (OIE) 
and other sources, the current distribution of ILT is described in Figure 6 (Pal et al., 
2009; Cabezas, 2012; Community, 2012; Health, 2012; Heinonen, 2012).  Red regions 
indicate countries positive for ILT between 2000 and 2012, and those illustrated with a 
grid pattern have been ILT positive for 10 years or greater.  Most apparent from this 
distribution is the proximity of these regions (marked in red and those with grids) to 
major poultry producing areas and to those areas that currently use or have used live-
attenuated vaccines (Table 2).  While licensed uses of live-attenuated vaccines are 
determined at the country, state, or province level, depending on the region of the world, 
presence of vaccine strains has been confirmed in the field even in some countries that 
disallow use of live attenuated-vaccines (Table 2) (Chacon & Ferreira, 2009; Neff et al., 
2008).   
 
4.2 Molecular Epidemiology 
Continual use of live-attenuated vaccines has shaped the molecular epidemiology 
of the virus, more so than outbreaks caused by wild-type strains.  Currently, the majority 
of outbreak related strains from commercial poultry are either indistinguishable from or 
closely related to vaccine strains (Oldoni et al., 2008), while outbreaks caused by wild-
type strains occur to a much lesser extent than those attributed to live-attenuated vaccine 
strains in commercial poultry. 
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Geographical	  
Region	  






Strains	  in	  the	  
Field	  
North	  America	   Trachivac,	  LT-­‐Blen,	  Laryngo-­‐
























Poulvac	  ILT	   Commercial	  &	  
non-­‐commercial	  
Yes	  







Africa	   No	  data	   Libya:	  not	  used	  
as	  of	  2011;	  no	  
other	  data	  
No	  data	  
Middle	  East	   ILT-­‐Abic	   Israel:	  
commercial	  &	  
non-­‐commercial;	  
Turkey:	  not	  used	  
as	  of	  2007;	  no	  
other	  data	  
Yes	  











BAL-­‐ILTTM,	  Belstar	   Philippines	  as	  of	  
2002,	  banned;	  
no	  other	  data	  
Yes	  
Australia	   SA-­‐2,	  A20,	  Serva	   Commercial	  &	  
non-­‐commercial	  
Yes	  
New	  Zealand	   Laryngo-­‐vac	   Commercial	  and	  
non-­‐commercial	  	  
No	  data	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Table	  2:	  Examples	  of	  current	  live-­‐attenuated	  vaccines	  and	  licensed	  uses.  While live-
attenuated vaccine use is not licensed in some regions of the world, vaccine strains have 
still be isolated from the field in countries without licensed use of these vaccines.  This 
illustrates the possibility of these	  strains	  lingering	  in	  host	  reservoirs	  from	  past	  points	  
in	  time	  when	  live-­‐attenuated	  vaccines	  may	  have	  been	  permitted	  in	  these	  countries,	  
and	  the	  ability	  of	  live-­‐attenuated	  vaccines	  to	  move	  across	  borders	  regardless	  of	  
licensing	  and	  biosecurity.	  (Chang	  et	  al.,	  1997;	  Han	  &	  Kim,	  2001;	  Saepulloh	  &	  Rovira,	  
2003;	  Kirkpatrick	  et	  al.,	  2006b;	  Noormohammadi	  &	  Kirkpatrick,	  2006;	  Creelan	  et	  al.,	  
2007;	  Oldoni	  &	  Garcia,	  2007a;	  Neff	  et	  al.,	  2008;	  Chacon	  et	  al.,	  2010;	  Diallo	  et	  al.,	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Recently, investigation into molecular markers responsible for reversion of 
GaHV-1 to virulence has unveiled or confirmed genomic regions suspected to be viral 
virulence factors.  Initially, methods to differentiate vaccine and wild-type viruses 
established different groupings of GaHV-1 strains based on polymerase chain reaction 
restriction fragment length polymorphisms (PCR-RFLP) and sequencing data in different 
regions of the world.  By means of these distinctions, sequence comparison of low and 
high virulence strains revealed SNPs and INDELs among strains, with specific attention 
given to non-synonymous amino acid changes found within gene products associated 
with classic herpesviral immune evasion strategies and viral virulence, as well as those 
unique to GaHV-1 (Lee et al., 2011c; Spatz et al., 2012).  Discovery of the molecular 
markers responsible for GaHV-1 reversion to virulence will potentially identify targets 
for genetic manipulation and point to a promising future for the development of novel 
control strategies.  If advances are to be made in the control of the disease, it will be 
pivotal to incorporate associations related to virulence and attenuation through 
epidemiological investigation of GaHV-1 at the molecular level. 
At the foundation of ILT molecular epidemiology lie techniques aimed at 
differentiation of virus genotypes.  However, because strains of ILT have no 
serospecificity, molecular methods such as PCR-RFLP and DNA sequencing have been 
used to draw epidemiological conclusions.  While identification of strain type does not 
necessarily stop or change current control measures, defining strains responsible for 
disease allow for poultry companies involved in or near an outbreak to take specific 
actions regarding biosecurity and vaccination programs.  Modification of vaccination 
strategies, biosecurity, and clean-out techniques are pivotal in controlling continuous 
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outbreaks.  However, efforts made to improve outbreak response remain challenging.  In 
Australia, the introduction of the European-origin Serva CEO vaccine to a population of 
birds previously vaccinated with the native vaccines, SA-2 and A20, resulted in 
emergence of virulent strains responsible for outbreaks of the disease.  Full genome 
sequencing clearly indicated that a recombination event between the native SA-2 and 
A20 with the CEO Serva strain may have influenced the emergence of the new virulent 
genotypes identified as classes 8 and 9 (Lee et al., 2012b).  In the United States, 
outbreak-related strains are mostly derived from CEO vaccines that circulate in the field 
due to sub-optimal vaccine administration in combination with poor biosecurity 
measures.  Both DNA sequencing and PCR-RFLP have been critical in strain 
differentiation and in understanding the emergence of virulent virus.  
 
4.2.1 Strain Genotyping by PCR-RFLP 
Target genes for detection and strain differentiation are regionally dependent, 
with each region of the world requiring its own optimal set of genes for differentiation.  
Table 3 outlines target genes for GaHV-1 detection, as well as PCR-RFLP and 
sequencing differentiation by region of the world.  However, these gene specifications are 
not concrete and, as made apparent by the recent recombination of vaccine viruses in 
Australia, changes in these targets may occur with time and as vaccine strategies evolve.   
Initially, PCR-RFLP was the method of choice for strain differentiation and 
involves differentiation of virus strains by restriction enzyme cleavage patterns of 
targeted genes.  Within the United States, 9 groups with unique PCR-RFLP patterns have 
been identified using genes ORFB-TK, gM, ICP4, and gG (Oldoni & Garcia,  
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Table	  3:	  Target	  genes	  for	  PCR-­‐RFLP	  strain	  differentiation,	  sequencing	  and	  PCR	  
strain	  differentiation,	  and	  detection	  of	  GaHV-­‐1.	  	  Due	  to	  single	  nucleotide	  
polymorphisms	  (SNPs)	  and	  insertions	  and	  deletions	  (INDELs)	  among	  strains	  of	  
different	  geographical	  origin,	  target	  genes	  for	  strain	  differentiation	  and	  detection	  
differ	  by	  region	  of	  the	  world.	  	  However,	  due	  to	  the	  constant	  evolution	  of	  field	  strains	  
and	  vaccination	  programs,	  as	  exemplified	  by	  the	  recombination	  of	  three	  vaccine	  
strains	  in	  Australia	  (Lee	  et	  al.,	  2012b),	  target	  genes	  should	  be	  evaluated	  prior	  to	  
investigation.	  	  *Contains	  ORFB,	  ORFC,	  ORFD,	  ORFE,	  gH,	  and	  TK	  genes.	  (Chang	  et	  al.,	  
1997;	  Vogtlin	  et	  al.,	  1999;	  Han	  &	  Kim.,	  2001;	  Humberd	  et	  al.,	  2002;	  Pang	  et	  al.,	  2002;	  
Han	  &	  Kim,	  2003;	  Kirkpatrick	  et	  al.,	  2006b;	  Noormohammadi	  &	  Kirkpatrick,	  2006;	  
Ojkic	  et	  al.,	  2006;	  Callison	  et	  al.,,	  2007;	  Creelan	  et	  al.,	  2007;	  Gulacti	  et	  al.,	  2007;	  
Oldoni	  &	  Garcia,	  2007a;	  	  Oldoni	  &	  Garcia,	  2007b;	  Chacon	  &	  Ferreira,	  2008;	  Neff	  et	  
al.,	  2008;	  Callison	  et	  al.	  2009;	  Chacon	  &	  Ferreira,	  2009;	  Rashid	  et	  al.,	  2009;	  Chacon	  
et	  al.,	  2010;	  Diallo	  et	  al.,	  2010;	  Moreno	  et	  al.,	  2010;	  Xie	  et	  al.,	  2010;	  Mahmoudian	  et	  
al.,	  2011;	  Sadeghi	  et	  al.,	  2011;	  Cabezas,	  2012;	  Chen	  et	  al.,	  2012;	  Halami	  et	  al.,	  2012;	  









Genes	  &	  Restriction	  
Enzymes	  
Sequencing	  &	  PCR	  
Target	  Genes	  




gM,	  gG,	  UL47,	  ICP4,	  
ORF	  B-­‐TK*	  (HaeIII,	  
MwoI,	  HinPII,	  BstF5I)	  
ICP4,	  UL47,	  gG,	  gM,	  
gB	  	  
gC,	  gE,	  ICP4	  
South	  
America	  
TK,	  UL47/gG,	  ICP4	  
(HaeIII,	  MspI,	  HinP1I)	  
ICP4	   gE	  
United	  
Kingdom	  
TK,	  ICP4	  (HaeI,	  Sau96,	  
NciI,	  MspI)	  
TK,	  ICP4	   ICP4	  
Europe	   gE,	  gG,	  ICP18.5,	  TK,	  
ORFB-­‐TK	  (EaeI,	  MspI,	  
HaeIII,	  FokI)	  	  
TK,	  ORFB-­‐TK,	  
ICP18.5,	  gE,	  gG,	  ICP4	  	  
gC	  
Africa	   No	  Data	   ICP4	   gE	  
Middle	  East	   gG,	  TK	  (BamHI,	  HaeIII)	   ICP4	   TK,	  ICP4	  
East	  Asia	  
	  
gG,	  TK,	  ICP4	  (MspI,	  
HaeIII,	  Hinp1I)	  
gC,	  gG	  gE,	  gJ,	  TK,	  ICP4	   TK	  
South	  Asia	   No	  data	   TK	   TK	  
Australia	   gG,	  TK,	  ICP4,	  ICP18.5,	  
ORFB-­‐TK*	  (MspI,	  
HaeIII,	  FokI)	  
TK	   UL15	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2007a).  The resulting groupings consisted of the USDA reference strain in group I, the 
TCO vaccine strain in group II, field isolates closely related to the TCO vaccine in group 
III, CEO vaccine strains and CEO identical commercial poultry isolates in group IV, 
commercial poultry isolates closely related to the CEO vaccine in group V, vaccine-
unlike commercial poultry isolates in group VI, and unique backyard flock isolates in 
groups VII, VIII, and IX.   
Alternatively, in Australia five classes of strains were originally compiled based 
on PCR-RFLP differentiation using a combination of gG, TK, ICP4, and ICP18.5 target 
genes.  Class 1 consisted of the SA-2 and A20 CEO vaccines as well as related strains, 
classes 2 and 3 of vaccine-unlike field strains, class 4 of the Australian CSW virulent 
field strain, and class 5 of vaccine-like and –unlike field strains (Kirkpatrick et al., 
2006b).  In 2011, four new classes were identified, including class 6 strains isolated from 
the region of Victoria, the Nobilis (Serva) ILT vaccine in class 7, and the SA-2, A20, 
Serva recombinants in classes 8 and 9 (Blacker, 2011; Lee et al., 2012b). 
In South America, based on PCR-RFLP of the TK and gG genes, five patterns 
were identified among Brazilian and Peruvian field isolates (Chacon & Ferreira, 2009).  
Pattern A consisted of isolates from the Sao Paulo state of Brazil, pattern B isolates 
originated in southern Brazil, pattern C isolates originated in Peru, pattern D 
corresponded to the TCO vaccine, and pattern E to the CEO vaccine. 
In Taiwan, based on PCR-RFLP of gG, TK, and ICP4, three groups of strains 
were identified (Chang et al., 1997).  Group 1 consisted of the TCO vaccine and TCO-
like field strains, Group 2 of the CEO vaccine and CEO-like field strains, and Group 3 of 
vaccine-unlike field strains.  In Korea, three groups of field strains were differentiated 
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using the TK gene alone (Han & Kim, 2001).  Group 1 consisted of virulent strains, 
group 2 of low-virulence strains, and group 3 of vaccine strains.  In the latter example, 
the level of differentiation did not match that of other similar studies because only one 
target gene was utilized, outlining the importance of using multiple genes in PCR-RFLP 
differentiation.  However, despite the level of differentiation, the PCR-RFLP method 
initially revealed the presence of circulating vaccine-like strains as a source of disease 
outbreaks across the globe.  A summary of the target genes and corresponding restriction 
enzymes utilized for PCR-RFLP analysis are displayed in Table 3 according to region of 
the world. 
 
4.2.2 Strain Genotyping by DNA Sequencing 
In recent years, PCR-RFLP has been steadily replaced with DNA sequencing for 
strain differentiation, although this technique remains a less costly option for certain 
regions of the world.  One main advantage of sequencing over PCR-RFLP is that the data 
produced is easier to document, analyze, and maintain, whereas PCR-RFLP can be highly 
subjective. Also, sequencing is also more precise, especially when multiple target genes 
are utilized for differentiation.  
Like PCR-RFLP, target genes amplified and sequenced for strain differentiation 
are regionally dependent and are summarized in Table 3.  In North America, target genes, 
sequenced either in their entirety or partially, include ICP4, UL47, gB, gG and gM (Ojkic 
et al., 2006; Oldoni & Garcia, 2007b; Callison et al., 2009).  In South America, the ICP4 
gene has been sequenced (Chacon & Ferreira, 2009; Chacon et al., 2010), and in the 
United Kingdom the TK and ICP4 genes (Creelan et al., 2007).  In Europe, larger scale 
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investigation has been performed including the target genes TK, ICP4, gG, gE, ORFB-
TK (containing the gene regions ORFB, ORFC, ORFD, ORFE, gH, to TK), and ICP18.5 
(Neff et al., 2008; Moreno et al., 2010).  The target gene ICP4 has been successfully 
utilized in both Africa and the Middle East (Sadeghi et al., 2011; Halami et al., 2012), 
and the TK gene in South Asia (Sridevi et al., 2012).  Strains in East Asia have been 
successfully sequenced and differentiated using the target genes TK, ICP4, gC, gG, gE, 
gJ (Chen et al., 2012; Han & Kim., 2001), and in Australia the genes TK and gG have 
been used (Diallo et al., 2010).  No sequencing data has been published for Russia or 
Southeast Asia. 
 
4.2.3 Optimal Methods for Strain Genotyping 
Between PCR-RFLP and sequencing, two of the genes that have been most 
widely used for differentiation and molecular epidemiologic analysis of GaHV-1 are the 
TK and ICP4 genes.  In addition to being costly and time consuming, sequencing of 
multiple genes requires large amounts of viral DNA, which may require further virus 
isolation.  Alternatively, sequencing of TK and ICP4, either in their entirety or as partial 
gene sequences, is common and has been successful in differentiating field and vaccine 
strains of GaHV-1.  Although this method is not optimal, lacking some of the 
discriminatory power necessary to differentiate among GaHV-1 isolates, sequencing 
these genes in their entirety or partially has been a useful, cost effective, and rapid 
method to differentiate strains from several regions of the world.  Table 4 outlines by 
region of the world those laboratories that have differentiated strains by the amplification 
and sequencing of the TK and ICP4 gene segments. 
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Table	  4:	  Amplified	  regions	  of	  TK	  and	  ICP4	  for	  DNA	  sequencing.	  	  In	  recent	  years,	  PCR-­‐
RFLP	  has	  been	  steadily	  replaced	  with	  DNA	  sequencing	  for	  strain	  differentiation,	  although	  
PCR-­‐RFLP	  remains	  a	  less	  costly	  option	  for	  certain	  regions	  of	  the	  world.	  	  While	  there	  is	  a	  
range	  of	  target	  genes	  used	  for	  sequencing	  differentiation,	  as	  displayed	  in	  Table	  3,	  TK	  and	  
ICP4	  have	  been	  successfully	  used	  across	  regions.	  	  Sequencing	  of	  these	  two	  genes	  alone	  
can	  cut	  cost	  and	  time,	  although	  with	  a	  reduction	  in	  the	  level	  of	  discriminatory	  power.	  	  
Included	  are	  the	  regions	  of	  each	  gene	  amplified	  in	  previous	  publications	  and	  the	  
corresponding	  GenBank	  accession	  number.	  (Creelan	  et	  al.,	  2007;	  Neff	  et	  al.,	  2008;	  Callison	  















Geographical	  Region	   Genes	   Amplified	  Region	   GenBank	  Accession	  No.	  
North	  America	   ICP4	   1807-­‐3052	   L32139	  
South	  America	   TK	   183-­‐831	   JN580313	  
ICP4	   205-­‐822	   JN580313	  
ICP4	   3796-­‐4381	   JN580313	  
United	  Kingdom	   ICP4	   714-­‐935	   JN580313	  
Europe	   TK	   3379-­‐5546	   DD00565	  
Middle	  East	   ICP4	   181-­‐856	   JN580313	  
ICP4	   3773-­‐4395	   JN580313	  
Australia	   TK	   691-­‐1085	   JN580313	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Despite the advantages of partial sequencing of the TK and ICP4 genes, use of 
PCR-RFLP plus sequencing is a more precise method for differentiating vaccines from 
vaccine derived field isolates, and multilocus analysis of at least two genes is optimal 
(Table 3).  Scientists from across the world have employed a combination of these 
methods in order to obtain maximal information to analyze differences between vaccine 
and non-vaccine strains.  In the United States, a combination of reverse restriction 
fragment length polymorphism (RRFLP), a method using both PCR-RFLP and real-time 
PCR, and DNA sequencing of the ICP4 gene have be exploited to genotype strains 
(Callison et al., 2009).  In Canada, PCR-RFLP of target genes ICP4, UL47, gE, and gG 
has been combined with sequencing of UL47 and gG (Ojkic et al., 2006), while in Brazil 
PCR-RFLP of the TK, ICP4, gG, and gE genes has been combined with sequencing of 
the TK and ICP4 genes (Chacon & Ferreira, 2009; Chacon, et al., 2010).  In the United 
Kingdom, PCR-RFLP of TK and ICP4 has been combined with sequencing of ICP4 
(Creelan et al., 2007), and in Europe PCR-RFLP of gE, gG, ICP18.5, ORFB-TK, and TK 
has been combined with sequencing of ICP4, TK, gE, gG, ORFB-TK, and the gene 
region spanning from ICP18.5 to UL43 (Neff et al., 2008; Moreno et al., 2010).  In 
Korea, PCR-RFLP and sequencing of the TK and gG genes has been combined (Han & 
Kim., 2001), and in Australia PCR-RFLP and sequencing have been done using only the 
TK gene (Diallo et al., 2010). 
 
4.2.4 Full Genome Sequencing 
So far, none of the genotyping methods outlined above has been successful in 
relating strain genotype to pathotype.  Some evidence indicates that changes in TK may 
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be related to virulence of Korean isolates (Han & Kim., 2001).  However, it is essential 
that this be further investigated and verified by introduction of changes related to 
attenuation in the TK gene into a virulent strain to determine if this confers some degree 
of attenuation.  In 2011, the first non-composite genome of GaHV-1 was sequenced for 
the Serva vaccine strain (Lee et al., 2011c), and Table 5 shows the 17 strains to date for 
which full genome sequences have been reported in GenBank and their corresponding 
pathotype. 
In an attempt to identify genetic determinants of attenuation in vaccine strains and 
virulence in field isolates, comparison of full genome sequences among vaccine and field 
isolates has been recently documented.  Comparison of the Australian Serva vaccine 
strain to four virulent GaHV-1 strains from the United States genotype groups I-VI 
revealed non-synonymous amino acid changes exclusive to the vaccine.  While some 
changes occurred among structural glycoproteins, suspected to account for geographical 
differences between strains, those found in the non-structural proteins UL28, UL5, and 
ICP4 are suspected to relate to virulence or attenuation due to their roles in genetic 
function of the virus (Spatz et al., 2012).  Additionally, the effect of further attenuation of 
the SA-2 vaccine was investigated by comparison of full genome sequences of the related 
SA-2 and A20 vaccines from Australia.  Only two non-synonymous amino acids changes 
were identified in the ORF B and UL15 non-structural proteins, representing two genes 
specifically affected by attenuation (Lee et al., 2011b).  Further comparison of complete 
genome sequences from differing genotypic classes, in addition to specific investigation 
of ICP4, UL28, UL5, ORF B, UL15 and other identified genes of interest, will ultimately  
 
	   44	  
	  
Table	  5:	  GaHV-­‐1	  full	  genome	  sequences.	  	  The	  first	  full	  genome	  sequence	  of	  GaHV-­‐1	  
became	  available	  in	  2011	  (Lee	  et	  al.,	  2011c),	  and	  to	  date	  there	  are	  17	  full	  genome	  
sequences	  of	  varying	  genotypes,	  each	  provided	  in	  this	  table	  with	  their	  
corresponding	  GenBank	  accession	  numbers.	  	  The	  availability	  of	  the	  full	  sequences	  of	  
these	  various	  genotypes	  has	  allowed	  for	  high	  and	  low	  virulence	  strain	  comparisons,	  
identifying	  potential	  genes	  involved	  in	  virulence	  reversion	  (Lee et al., 2011b; Spatz et 
al., 2012).	  	  Further	  genomic	  investigation	  is	  important	  to	  advancing	  understanding	  





Isolate	   Virulence	   Origin	   GenBank	  Accession	  
No.	  
A20	  Vaccine	   High	  
Attenuation	  
Australia	   JN596963	  
Australia	  Class	  8	   Virulent	   Australia	   JN804826	  
Australia	  Class	  9	   Virulent	   Australia	   JN804827	  
CEO	  High	  Passage	   Virulent	   United	  States	   JN80316	  
CEO	  Low	  Passage	   Moderate	  
Attenuation	  
United	  States	   JN580317	  
CEO	  TRVX	   Moderate	  
Attenuation	  





United	  States	   JQ083494	  
LT-­‐Blen	  CEO	  Vaccine	   Moderate	  
Attenuation	  
United	  States	   JQ083493	  
SA2	  Vaccine	   Moderate	  
Attenuation	  
Australia	   JN596962	  





TCO	  High	  Passage	   Mild	  Virulence	   United	  States	   JN580314	  
TCO	  IVAX	   High	  
Attenuation	  
United	  States	   JN580312	  
TCO	  Low	  Passage	   High	  
Attenuation	  
United	  States	   JN580315	  
USDA	  Reference	  Strain	   Virulent	   United	  States	   JN542534	  
1874C5	  Broiler	  Isolate	   Virulent	   United	  States	   JN542533	  
63140	  Broiler	  Isolate	   Virulent	   United	  States	   JN542536	  
81658	  Broiler	  Breeder	  
Isolate	  
Mild	  Virulence	   United	  States	   JN542535	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reveal genes associated with attenuation and virulence of GaHV-1 and increase 
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Chapter	  5:	  ILT	  Host-­‐Pathogen	  Interactions 
 
	   In	  recent	  years,	  in	  addition	  to	  genomic	  characterization	  of	  GaHV-­‐1	  genotypes,	  
and	  investigation	  into	  virus-­‐specific	  attenuation	  mechanisms,	  investigation	  into	  host	  
specific	  pathways	  following	  infection	  has	  begun.	  	  Little	  research	  has	  been	  done	  
regarding	  host-­‐pathogen	  interactions	  of	  GaHV-­‐1	  and	  the	  chicken	  genome,	  however	  
recent	  research	  into	  GaHV-­‐1	  epigenetics	  has	  investigated	  changes	  in	  host	  gene	  
expression	  based	  on	  infection.	  	  Identification	  of	  genes	  that	  result	  in	  host	  resistance	  
to	  infection,	  and	  selecting	  for	  these	  genes	  in	  lines	  of	  commercial	  poultry,	  represents	  
an	  additional	  strategy	  that	  could	  be	  developed	  in	  order	  to	  prevent	  infection.	  	  The	  
basis	  for	  these	  epigenetic	  investigations	  began	  with	  past	  field	  observations	  of	  
breeds	  with	  more	  or	  less	  resistance	  to	  infection.	  
	  
5.1	  Past	  Field	  Observations 
According	  to	  past	  field	  observations,	  differences	  in	  susceptibility	  to	  GaHV-­‐1	  
infection	  have	  been	  described.	  	  Single	  comb	  white	  leghorns	  have	  been	  noted	  as	  a	  
more	  resistant	  breed,	  while	  broiler	  breeds	  are	  typically	  less	  resistant,	  and	  
reproduction	  of	  infection	  in	  a	  laboratory	  setting	  easier	  in	  broilers	  than	  in	  layers	  or	  
specific	  pathogen	  free	  (SPF)	  chickens	  (Zavala,	  2011).	  	  One	  possible	  source	  of	  these	  
differences	  in	  susceptibility	  is	  the	  increased	  level	  of	  Cornish	  type	  genes	  which	  
broilers	  carry	  today. 
 
	  
	   47	  
5.2	  MHC	  Allele-­‐based	  Resistance 
In	  further	  genetic	  investigation	  of	  these	  differences	  in	  susceptibility,	  birds	  
with	  defined	  major	  histocompatibility	  complex	  (MHC)	  phenotypes	  have	  shown	  
differential	  response	  to	  infection	  (Loudovaris	  et	  al.,	  1991a).	  	  Specifically,	  birds	  
expressing	  the	  B113	  MHC	  allele	  are	  relatively	  resistant	  to	  GaHV-­‐1	  infection	  and	  birds	  
expressing	  the	  B114	  MHC	  allele	  are	  relatively	  susceptible	  to	  infection.	  	  In	  comparison	  
to	  birds	  expressing	  the	  B114	  allele,	  those	  expressing	  the	  B15	  MHC	  allele	  are	  
increasingly	  susceptible	  to	  infection.	  	  Additionally,	  macrophages	  from	  birds	  
expressing	  the	  B113/113	  MHC	  allele	  or	  the	  B114/114	  MHC	  allele	  express	  a	  greater	  
proportion	  of	  GaHV-1	  antigen	  after	  in	  vitro	  infection	  compared	  to	  those	  expressing	  
the	  B15/15	  MHC	  allele,	  suggesting	  macrophages	  from	  the	  two	  relatively	  resistant	  
genetic	  B113	  and	  B114	  lines	  of	  birds	  may	  be	  able	  to	  better	  recognize,	  process,	  and	  
present	  viral	  antigen	  to	  the	  immune	  system	  (Loudovaris	  et	  al.,	  1991b).	  	  
Furthermore,	  birds	  expressing	  the	  B2B2	  MHC	  allele	  can	  mount	  a	  more	  efficient	  
protective	  immune	  response	  to	  low	  infective	  doses	  of	  virulent	  infection,	  while	  birds	  
expressing	  the	  B2B15	  MHC	  allele	  require	  a	  10-­‐fold	  higher	  dose	  to	  mount	  a	  protective	  
immune	  response,	  and	  birds	  expressing	  the	  B15B21	  MHC	  allele	  are	  altogether	  unable	  
to	  mount	  a	  protective	  immune	  response	  (Poulsen	  et	  al.,	  1998). 
 
5.3	  Epigenetics 
Changes	  in	  host	  gene	  expression,	  based	  on	  GaHV-­‐1	  infection,	  have	  also	  
recently	  been	  investigated	  and	  functional	  pathways	  responsive	  to	  infection	  
uncovered.	  	  Based	  on	  in	  vitro	  infection	  with	  virulent	  virus,	  Lee	  et	  al.	  (2010)	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identified	  789	  host	  genes	  which	  are	  differentially	  expressed	  during	  GaHV-­‐1	  
infection,	  with	  275	  of	  these	  genes	  connected	  to	  21	  possible	  gene	  networks	  classified	  
in	  functional	  groups	  including	  cancer,	  genetic	  disorders,	  cellular	  growth,	  cellular	  
proliferation,	  and	  cell	  death.	  	  Of	  the	  21	  gene	  networks,	  6	  gene	  networks	  are	  identical	  
at	  all	  time	  points.	  	  Further	  investigation	  of	  these	  networks	  by	  Lee	  et	  al.	  (2010)	  
revealed	  the	  Network	  1	  pathway	  to	  be	  closely	  associated	  with	  the	  IL6	  signaling	  
pathway,	  suggesting	  that	  GaHV-­‐1	  increases	  IL6	  expression	  and	  subsequently	  
inhibits	  cellular	  proliferation	  through	  downregulation	  of	  the	  proliferation	  enhancer	  
Janus	  kinase	  1	  (JAK).	  	  Network	  2	  contains	  several	  downregulated	  heat	  shock	  
proteins	  (HSP)	  thought	  to	  be	  responsible	  for	  erroneous	  viron	  structures	  and	  a	  
source	  of	  low	  GaHV-­‐1	  titers	  typical	  to	  tissue	  culture	  infection.	  	  The	  genes	  of	  network	  
3	  include	  growth	  factors	  and	  matrix	  metalloproteinases	  (MMPs),	  with	  expression	  
profiles	  consistent	  with	  those	  seen	  during	  other	  herpesvirus	  infections	  and	  involved	  
in	  extracellular	  remodeling,	  tissue	  invasion,	  and	  angiogenesis.	  	  Networks	  4,	  5,	  and	  6	  
contain	  genes	  encoding	  for	  IFNβ, IL1β, CCL20, CCL4, NF-κβ, NFIB, IL1, and ID1 
specific	  to	  the	  host	  immune	  response	  to	  pathogenic	  infection. 
In	  comparison	  to	  virulent	  infection,	  in	  vitro	  infection	  with	  vaccine	  virus	  by	  
Lee	  et	  al.	  (2012a)	  revealed	  213	  differentially	  expressed	  host	  genes,	  divided	  into	  10	  
possible	  gene	  networks,	  and	  grouped	  into	  functional	  categories	  including	  tissue	  
development,	  cellular	  growth,	  cellular	  proliferation,	  cellular	  movement,	  and	  
inflammatory	  response.	  	  Additionally,	  of	  the	  213	  differentially	  expressed	  host	  genes,	  
bone	  morphogenetic	  protein	  2	  (BMP2),	  chromosome	  8	  open	  reading	  frame	  79	  
(C8orf79),	  coagulation	  factor	  X	  (F10),	  and	  neuropeptide	  Y	  (NPY)	  are	  expressed	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distinctly	  during	  vaccine	  infection	  when	  compared	  to	  virulent	  infection.	  	   
While	  genetic	  markers	  responsible	  for	  host	  response	  and	  resistance	  to	  
infection	  have	  been	  identified,	  broad	  integration	  of	  these	  findings	  into	  production	  
strategies	  has	  yet	  to	  be	  undertaken.	  	  Research	  into	  these	  scientific	  sectors	  remains	  
in	  the	  early	  stages	  related	  to	  GaHV-­‐1,	  limiting	  current	  developments.	  	  However,	  
possibilities	  such	  as	  incorporation	  of	  breed	  resistance	  genes	  in	  production	  lines	  of	  
birds	  represents	  an	  additional	  protective	  strategy	  which	  could	  ultimately	  be	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Chapter	  6:	  Potential	  for	  Future	  Eradication	  of	  ILT 
 
6.1	  Eradication	  Potential	  of	  ILT 
In	  1995,	  Bagust	  &	  Johnson	  examined	  the	  virus-­‐host	  interactions	  of	  ILT	  as	  
related	  to	  the	  prospect	  for	  eradication	  of	  the	  pathogen	  by	  the	  year	  2000	  (Bagust	  &	  
Johnson,	  1995).	  	  As	  it	  stands,	  we	  are	  12	  years	  past	  this	  postulated	  date	  for	  
eradication	  and	  GaHV-­‐1	  remains	  a	  worldwide	  pathogen	  that	  causes	  significant	  
economic	  damage	  to	  the	  poultry	  industry	  on	  an	  annual	  basis.	  	  Establishment	  of	  
latency	  remains	  a	  critical	  issue	  regarding	  spread	  of	  both	  wild	  type	  and	  vaccine	  
strains	  of	  the	  virus.	  	  The	  current	  vaccine	  options,	  coupled	  with	  current	  management	  
practices,	  are	  not	  sufficient	  in	  combating	  the	  ability	  of	  the	  virus	  to	  establish	  latency	  
and	  thus	  result	  in	  a	  constant	  pool	  of	  infection	  upon	  highly	  predictable	  reactivation. 
 
6.2	  Factors	  Associated	  with	  Eradication	  Potential	   
Bagust	  and	  Johnson	  (1995)	  cited	  eight	  factors	  associated	  with	  the	  eradication	  
potential	  of	  ILT	  including,	  (1)	  the	  virus	  is	  not	  egg	  transmitted,	  (2)	  infection	  is	  
essentially	  confined	  to	  chickens,	  (3)	  levels	  of	  infectivity	  are	  usually	  low,	  (4)	  spread	  
of	  infection	  can	  be	  strongly	  confined	  by	  industry	  precautions,	  (5)	  virus	  infectivity	  is	  
easily	  inactivated	  outside	  of	  the	  host,	  (6)	  immunity	  will	  absolutely	  protect	  against	  
challenge,	  (7)	  immunity	  to	  GaHV-­‐1	  is	  cell-­‐mediated,	  (8)	  and	  GaHV-­‐1	  strains	  are	  
antigenically	  homogeneous,	  which	  will	  be	  discussed	  in	  the	  following	  sections. 
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6.2.1	  Host	  Restriction 
While	  ILT	  has	  been	  reported	  in	  turkeys,	  pheasants,	  and	  peafowl	  (Hilbink,	  
1985;	  Kaleta	  &	  Redmann,	  1997;	  Portz	  et	  al.,	  2008),	  these	  bird	  populations	  are	  
comparatively	  small	  versus	  broiler,	  layer,	  and	  breeder	  populations	  in	  major	  poultry	  
producing	  countries.	  	  Additionally,	  there	  have	  yet	  to	  be	  major	  outbreaks	  of	  ILT	  
reported	  in	  a	  non-­‐chicken	  species.	  	  While	  chickens	  remain	  the	  primary	  host	  
reservoir	  of	  the	  virus,	  control	  of	  disease	  outbreaks	  in	  commercial	  and	  backyard	  
flocks	  could	  help	  towards	  eradication	  of	  the	  disease,	  a	  goal	  that	  could	  ultimately	  be	  
attained	  if	  vaccines	  which	  do	  not	  permit	  establishment	  of	  latency,	  development	  of	  
carrier	  birds,	  and	  reversion	  to	  virulence	  were	  created.	  	  Additional	  consideration	  for	  
wild	  populations	  of	  birds,	  however,	  would	  also	  have	  to	  be	  taken	  into	  account. 
 
6.2.2	  Egg	  Transmission 
As	  discussed	  in	  section	  2.5,	  while	  maternal	  antibodies	  are	  passed	  to	  
offspring,	  they	  do	  not	  confer	  protection,	  nor	  do	  they	  interfere	  with	  vaccination.	  	  
Additionally,	  ILT	  is	  not	  vertically	  transmitted	  from	  parent	  to	  offspring	  in	  ovo.	  	  The	  
lack	  of	  egg	  transmission	  is	  hugely	  advantageous	  to	  prospective	  eradication	  efforts	  
and	  the	  consideration	  of	  parental	  disease	  state	  does	  not	  interfere	  with	  current	  
disease	  control	  programs. 
 
6.2.3	  Viral	  Infectivity 
On	  average,	  high	  levels	  of	  viral	  shedding	  are	  sustained	  for	  approximately	  7	  
dpi.	  	  However,	  during	  this	  period,	  the	  virus	  is	  highly	  transmissible	  and	  easily	  able	  to	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spread	  from	  bird-­‐to-­‐bird	  and	  via	  personnel,	  equipment,	  and	  other	  fomites	  
commonly	  present	  in	  a	  production	  setting.	  	  While	  the	  period	  of	  viral	  shedding	  is	  
relatively	  short,	  control	  of	  the	  spread	  of	  disease	  is	  critical	  and	  successes	  in	  places	  
like	  California	  have	  been	  described	  through	  strict	  biosecurity	  measures	  
(Shivaprasad,	  2012).	  	  Since	  the	  discovery	  of	  ILT	  in	  the	  early	  20th	  century,	  biosecurity	  
has	  been	  an	  essential	  factor	  in	  disease	  control	  and	  will	  remain	  so	  in	  eradication	  
efforts. 
 
6.2.4	  Industry	  Precautions 
While	  the	  above-­‐mentioned	  industry	  precautions	  are	  successful	  in	  
decreasing	  disease,	  strict	  adherence	  to	  biosecurity	  regulations	  can	  be	  both	  difficult	  
to	  regulate	  and	  costly.	  	  New	  reservoirs	  of	  virus	  have	  also	  recently	  been	  uncovered,	  
including	  retention	  of	  CEO	  vaccine	  in	  water	  drinker	  lines	  due	  to	  biofilm	  formation,	  
leading	  to	  transmission	  of	  disease	  to	  birds	  up	  to	  21	  days	  following	  drinking	  water	  
vaccination	  (Ou	  et	  al.,	  2011).	  	  Additionally,	  wind-borne	  transmission	  of	  the	  virus	  and	  
other	  intangible	  forms	  of	  spread	  complicate	  control	  efforts	  (Johnson	  et	  al.,	  2005).	  	  
However,	  industry	  precautions	  remain	  a	  top	  priority,	  and	  if	  strictly	  followed,	  are	  
successful	  in	  eliminating	  disease	  on-­‐site	  and	  in	  a	  local	  radius.	  	  Precautions	  include	  
but	  are	  not	  limited	  to	  use	  of	  personal	  protective	  equipment	  (PPE),	  proper	  
disinfection	  of	  housing	  and	  production	  equipment,	  limited	  on-­‐farm	  traffic,	  and	  all-­‐
in-­‐all-­‐out	  production	  policies	  in	  which	  flocks	  of	  birds	  enter	  and	  exit	  a	  farm	  as	  a	  
whole	  and	  birds	  of	  different	  immune	  status	  are	  not	  intermingled.	  	  Additionally,	  
effective	  disinfection	  programs	  are	  critical,	  including	  sufficient	  contact	  time	  and	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biofilm-­‐reducing	  sanitizers,	  and	  employee	  education	  is	  pivotal	  to	  assuring	  an	  
understanding	  of	  disease	  transmission	  and	  ways	  to	  improve	  flock	  health	  and	  
production	  efficiency. 
 
6.2.5	  Viral	  Inactivation 
Following	  a	  disease	  outbreak	  and/or	  vaccination,	  complete	  disinfection	  and	  
cleanup	  becomes	  increasingly	  critical	  compared	  to	  the	  end	  of	  a	  typical	  production	  
cycle.	  	  As	  discussed	  in	  section	  2.6,	  GaHV-­‐1	  is	  easily	  inactivated	  outside	  of	  the	  host	  
using	  common	  disinfectants	  or	  low	  levels	  of	  heat.	  	  However,	  the	  importance	  of	  
following	  manufacturers’	  guidelines	  in	  terms	  of	  disinfectant	  dilution	  and	  contact	  
times	  are	  important,	  and	  the	  presence	  of	  organic	  matter	  during	  disinfection	  poses	  
an	  additional	  complication	  that	  increases	  required	  contact	  times	  beyond	  typical	  
manufacturers’	  recommendations	  (Ruano	  et	  al.,	  2001).	  	  However,	  the	  fact	  that	  
GaHV-­‐1	  inactivation	  is	  attained	  with	  relative	  ease	  using	  disinfectants	  and	  low-­‐level	  
heat	  decreases	  overall	  carryover	  and	  spread	  of	  the	  disease	  (Bagust et al., 2000). 
 
6.2.6	  Host	  Immune	  Protection 
Following	  live-­‐attenuated	  vaccination,	  protection	  against	  challenge	  virus	  
exposure	  is	  complete	  6	  to	  8	  days	  after	  vaccination	  and	  sustained	  for	  15	  to	  20	  weeks	  
post	  vaccination,	  although	  waning	  of	  immunity	  has	  been	  described	  as	  early	  as	  8	  
weeks	  post	  vaccination	  (Guy	  &	  Garcia,	  2008).	  	  Established	  immunity	  will	  absolutely	  
protect	  birds	  against	  challenge,	  thus	  preventing	  establishment	  of	  latency	  and	  of	  
carrier	  state	  birds.	  	  However,	  the	  value	  of	  revaccination	  following	  the	  15	  to	  20	  week	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marker	  is	  not	  definite,	  and	  prevention	  of	  vaccine	  virus	  replication	  due	  to	  
neutralization	  is	  suspected	  to	  inhibit	  protection	  (Izuchi	  et	  al.,	  1984;	  Fahey	  &	  York,	  
1990).	  	  Additionally,	  vaccination	  is	  not	  a	  standard	  practice,	  typically	  only	  performed	  
in	  endemic	  ILT	  regions,	  leaving	  many	  populations	  of	  birds	  susceptible	  as	  the	  virus	  
spreads. 
 Overall,	  while	  immunity	  will	  absolutely	  protect	  birds	  against	  infection	  as	  
Bagust	  and	  Johnson	  suggest,	  length	  of	  that	  immunity	  elicited	  by	  current	  vaccine	  
options	  is	  insufficient.	  	  The	  prospect	  of	  alternative	  vaccine	  options	  that	  elicit	  
sustained	  protection,	  or	  permit	  effective	  revaccination,	  is	  dependent	  on	  further	  
developments	  in	  ILT	  vaccinology.	  	  Other	  vaccine	  options	  such	  as	  viral	  vector	  
vaccines	  exist,	  however	  as	  discussed	  in	  section	  4.4,	  issues	  with	  establishment	  of	  an	  
immune	  response	  that	  is	  robust	  enough	  to	  fully	  protect	  birds	  still	  remain. 
 
6.2.7	  Host	  Cell-­‐mediated	  Immune	  Response 
As	  discussed	  in	  sections	  2.6	  and	  7.2.6,	  the	  main	  response	  to	  GaHV-­‐1	  infection	  
is	  cell	  mediated.	  	  While	  the	  fact	  that	  maternal	  antibodies	  do	  not	  interfere	  with	  
vaccination	  is	  advantageous	  as	  Bagust	  and	  Johnson	  suggest,	  the	  inability	  to	  
revaccinate	  due	  to	  virus	  neutralizing	  antibodies	  is	  hugely	  disadvantageous	  to	  ILT	  
protection	  programs.	  	  Account	  for	  this	  fact	  must	  be	  taken	  in	  development	  of	  future	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6.2.8	  Antigenetic	  Homogeneity 
At	  the	  core	  of	  the	  GaHV-­‐1	  virion	  is	  a	  dsDNA	  genome,	  which	  is	  relatively	  stable	  
and	  provides	  an	  advantageous	  backbone	  for	  vaccine	  development.	  	  GaHV-­‐1	  innately	  
lacks	  the	  quasi	  species	  conundrum	  of	  many	  RNA	  viruses	  because	  the	  virus	  does	  not	  
display	  antigenic	  variation,	  and	  cross-­‐neutralization	  and	  cross-­‐protection	  of	  known	  
GaHV-­‐1	  strains	  has	  been	  shown	  to	  occur	  (Russell	  &	  Turner,	  1983).	  	  This	  factor	  
conveys	  a	  large	  advantage	  to	  scientists	  and	  has	  allowed	  ILT	  vaccine	  research	  to	  
flourish,	  past	  and	  present,	  and	  ultimately	  defines	  the	  prospect	  of	  ILT	  eradication	  as	  
a	  possible	  feat.	  
In	  addition	  to	  these	  eight	  factors,	  Bagust	  and	  Johnson	  suggest	  consideration	  
of	  the	  benefit-­‐cost	  ratio	  and	  time	  scale	  for	  eradication	  of	  ILT.	  	  Their	  projection	  for	  
eradication	  of	  ILT	  from	  production	  sites	  by	  the	  year	  2000	  was	  based	  on	  quarantine,	  
and	  hygiene	  measures,	  in	  addition	  to	  genetically	  engineered	  vaccines.	  	  Quarantine	  
and	  hygiene,	  in	  the	  form	  of	  strict	  biosecurity,	  have	  proven	  to	  successfully	  prevent	  
the	  spread	  of	  the	  virus.	  	  However,	  vaccines	  have	  yet	  to	  be	  successfully	  developed	  in	  
a	  manner	  that	  would	  move	  poultry	  producers	  to	  discontinue	  live-­‐attenuated	  vaccine	  
use.	  	  As	  most	  field	  strains	  are	  indistinguishable	  from	  vaccine	  strains,	  discontinuing	  
live-­‐attenuated	  vaccine	  use	  would	  remove	  the	  largest	  source	  contributing	  to	  annual	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Chapter	  7:	  Summary	  &	  Conclusions 
  
GaHV-­‐1	  is	  a	  virus	  that	  remains	  analyzed	  to	  a	  much	  lesser	  extent	  than	  other	  
alphaherpesviruses,	  with	  much	  of	  biology	  of	  the	  virus	  based	  on	  HSV-­‐1.	  	  Further	  
development	  in	  the	  molecular	  characterization	  of	  the	  virus	  is	  pivotal	  to	  novel	  
vaccine	  development,	  an	  area	  currently	  concentrating	  on	  genetic	  engineering	  and	  
necessary	  to	  the	  end	  of	  live-­‐attenuated	  vaccine	  use.	  	  Vaccine	  related	  outbreaks	  have	  
been	  described	  since	  the	  development	  of	  ILT	  vaccines	  and	  remain	  the	  largest	  source	  
of	  virus	  in	  the	  field.	  	  If	  spread	  of	  the	  virus	  is	  to	  be	  stopped	  to	  a	  significant	  extent,	  
stopping	  the	  use	  of	  live-­‐attenuated	  vaccines	  represents	  a	  direct	  way	  to	  remove	  a	  
major	  source	  of	  virus	  from	  the	  environment.	  	  However,	  because	  the	  cost,	  ease	  of	  use,	  
and	  availability	  of	  the	  CEO	  and	  TCO	  live-­‐attenuated	  vaccines	  meets	  the	  needs	  of	  the	  
poultry	  industry,	  their	  use	  is	  still	  prevalent	  and	  continues	  to	  shape	  the	  molecular	  
epidemiology	  of	  the	  virus.	  	   
For	  each	  region	  of	  the	  world,	  there	  is	  an	  optimal	  set	  of	  target	  genes	  for	  
detection	  and	  differentiation	  of	  GaHV-­‐1	  related	  outbreak	  strains.	  	  However,	  with	  
recombination	  events	  like	  that	  which	  occurred	  with	  the	  SA-­‐2,	  A20	  and	  Serva	  vaccine	  
strains	  in	  Australia,	  modification	  of	  these	  target	  genes	  may	  be	  necessary	  with	  time	  
and	  change	  in	  local	  epidemiology	  of	  virus	  strains.	  	  New	  potential	  exists	  in	  epigenetic	  
research	  of	  host-­‐virus	  interactions,	  and	  those	  interactions	  involved	  in	  resistance	  
and	  susceptibility	  to	  the	  virus	  could	  be	  integrated	  into	  production	  lines	  of	  birds	  to	  
strengthen	  ILT	  protection	  programs.	  	  However,	  if	  continued	  thought	  of	  ILT	  
eradication	  is	  to	  be	  considered,	  ultimately,	  development	  of	  vaccines	  that	  provide	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sufficient	  immune	  protection	  while	  retaining	  the	  inability	  to	  revert	  to	  virulence,	  
establish	  latency,	  and	  create	  a	  carrier	  state	  in	  birds,	  will	  allow	  successful	  eradication	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Appendix 
 
Supplemental List 1: Global Distribution of ILT as of 2012 
Year of last report of disease in parenthesis; 2012 status yet to be reported  
in completion for all countries; sited from the OIE-WAHID ILT disease  
timeline unless otherwise noted (Health, 2012). 
	  
2000 to 2012 ILT+ 
1. Afghanistan (2012) 
2. Argentina (2012)⌘ 
3. Armenia (2005) 
4. Australia (2011)⌘ 
5. Austria (2007)* 
6. Bahrain (2011)v	  
7. Bangladesh (2010)* 
8. Belarus (2005) 
9. Belgium (2011)⌘ 
10. Benin (2010)* 
11. Bolivia (2011) 
12. Brazil (2010) 
13. Cameroon (2010)v	  
14. Canada (2012)⌘ 
15. Cape Verde (2009)*v	  
16. Central African  
Republic (2011) 
17. Chile (2012)⌘ 
18. China (2012)⌘ 
19. Columbia (2012)⌘ 
20. Congo (Dem. Rep. of) 
(2011) 
21. Costa Rica (2011) 
22. Cyprus (2011) 
23. Czech Republic (2011) 
24. Denmark (2012)⌘ 
25. Ecuador (2012) 
26. Eritrea (2009)*⌘ 
27. Ethiopia (2000) 
28. Finland (2012) 
29. France (2006)*⌘ 
30. French Polynesia(2011) 
31. Germany (2011)⌘ 
32. Greece (2000) 
33. Guam (2001)* 
34. Guinea (2004)* 
35. Hong Kong (2010) 
36. Hungary (2011)⌘	  
37. India (2009)1 
38. Indonesia (2007)* 
39. Iran (2000) 
40. Iraq (2012) 
41. Ireland (2012) 
42. Israel (2012) 
43. Italy (2011)v	  
44. Japan (2012)⌘ 
45. Kiribati (2012)¤	  
46. Korea, North (2010) 
47. Korea, South (2010)*⌘ 
48. Kuwait (2005) 
49. Lebanon (2011)⌘ 
50. Libya (2010) 
51. Malaysia (2007)⌘ 
52. Malta (2008) 
53. Mexico (2011)⌘ 
54. Morocco (2004)* 
55. Myanmar (2010)* 
56. Namibia (2007) 
57. Netherlands (2011)⌘ 
58. Nepal (2009) 
59. New Caledonia (2008) 
60. New Zealand (2012)⌘ 
61. Nigeria (2004)* 
62. Norway (2012)⌘ 
63. Pakistan (2011) 
64. Palestine (2010) 
65. Peru (2012) 
66. Philippines (2011)⌘ 
67. Poland (2007) 
68. Portugal (2008) 
69. Puerto Rico (2003) 
70. Reunion (2003) 
71. Russia (2006) 
72. Rwanda (2009) 
73. Samoa (2005)v	  
74. South Africa (2008)⌘ 
75. Swaziland (2001) 
76. Sweden (2012)⌘ 
77. Switzerland (2012)⌘ 
78. Syria (2008)* 
79. Taiwan (2010)⌘ 
80. Thailand (2004) 
81. Togo (2010) 
82. Trinidad & Tobago 
(2004) 
83. Turkey (2003)*	  
84. Turkmenistan (2010)* 
85. Uganda (2011)⌘ 
86. United Kingdom 
(2011)⌘ 
87. United States of 
America (2012)⌘ 
88. Ukraine (2004) 
89. Uruguay (2012)⌘ 
90. Uzbekistan (2004) 
91. Wallis & Futuna 
(2002)¤	  
92. Yemen (2006)* 
 
1999 and prior ILT+ 
1. Albania (1996)* 
2. Algeria (1989)* 
3. Brunei (1996) 
4. Bulgaria (1994) 
5. Burkina Faso (1999)* 
6. Chad (1972)* 
7. Cook Islands (1996)*¤	  
8. Egypt (1991) 
9. Gabon (1997) 
10. Georgia (1990) 
11. Kyrgyzstan (1992) 
12. Lesotho (1996) 
13. Luxembourg (1999) 
14. Malawi (1996) 
15. Mali (1996)* 
16. Mauritius (1994) 
17. Moldavia (1992) 
18. Mozambique (1998) 
19. Paraguay (1996) 
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20. Romania (1999) 
21. Saudi Arabia (1998)* 
22. Senegal (2000) 
23. Singapore (1989) 
24. Spain (1999)v	  
25. Sri Lanka (1994) 
26. Suriname (1997) 
27. Tanzania (1996)* 
28. Tunisia (1998) 
29. United Arab 
Emirates (1997) 









7. British Virgin 
Islands 




12. Dominican Republic 









22. Niger  
23. Sao Tome & 
Principe 
24. St. Barthélemy 
25. St. Kitts & Nevis 
26. St. Lucia 
27. St. Maarten 
28. Turks & Caicos 




















10. El Salvador 
11. Equatorial Guinea 
12. Estonia 
13. Fiji 




















34. San Marino 
35. Serbia 
36. Seychelles 










2. Congo (Rep. of) 
3. Cote d’Ivoire 
4. East Timor 
5. Falkland Islands 
6. Gambia 




11. Papua New Guinea 

































*	  Data unavailable after last GaHV-1+ reported year; current status unknown, however no literary 
evidence or reports of becoming disease free. 
	  
vLast reported year reported as a suspected year, however previous years confirmed GaHV-1 positive 
(Health 2012).	  
	  
⌘	  GaHV-1 positive for 10 years or greater (Health, 2012).	  
	  
¤The Secretariat of the Pacific Community currently sites “serologic evidence [of GaHV-1] in Cook 
Islands, Kiribati, Tonga, and Wallis and Futuna” (Community, 2012)	  
	  
1 In a search of all available GaHV-1 DNA sequences on GenBank, the GaHV-1 partial p32 gene 
sequence for isolate HBL/viral/AP/02/10 (GenBank accession number FN811131) was referenced as an 
isolate from a poultry farm in Tamilnadu, Namakkal, India from 19-Dec-2009 (Pal et al., 2009). 
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